Terms: = Kidney tumors AND CCND2, KIAK0002, 894, ENSG00000118971, P30279, MGC102758
51 results:
1. Bioinformatic Analysis and Clinical Case Studies Identify CD276 as a Promising Diagnostic Biomarker for Clear Cell Renal Cell Carcinoma.
Zhang Z; Xu J; Song Z; Zhang J; Lin Y; Ouyang J
Cancer Control; 2024; 31():10732748241250181. PubMed ID: 38669187
[TBL] [Abstract] [Full Text] [Related]
2. Increased level of serum leucine-rich-alpha-2-glycoprotein 1 in patients with clear cell renal cell carcinoma.
Nakanishi S; Goya M; Suda T; Yonamine T; Sugawa A; Saito S
BMC Urol; 2024 Apr; 24(1):94. PubMed ID: 38658967
[TBL] [Abstract] [Full Text] [Related]
3. Gene mutation profiling and clinical significances in patients with renal cell carcinoma.
Wang Y; He P; Zhou X; Wang C; Fu J; Zhang D; Liao D; Zhou Z; Wu C; Gong W
Clinics (Sao Paulo); 2023; 78():100259. PubMed ID: 37515929
[TBL] [Abstract] [Full Text] [Related]
4. Estimating health spending associated with chronic multimorbidity in 2018: An observational study among adults in the United States.
Chang AY; Bryazka D; Dieleman JL
PLoS Med; 2023 Apr; 20(4):e1004205. PubMed ID: 37014826
[TBL] [Abstract] [Full Text] [Related]
5. A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy.
Lin J; Cai Y; Ma Y; Pan J; Wang Z; Zhang J; Liu Y; Zhao Z
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982415
[TBL] [Abstract] [Full Text] [Related]
6. Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials.
Chihara D; Lin R; Flowers CR; Finnigan SR; Cordes LM; Fukuda Y; Huang EP; Rubinstein LV; Nastoupil LJ; Ivy SP; Doroshow JH; Takebe N
Lancet; 2022 Aug; 400(10351):512-521. PubMed ID: 35964611
[TBL] [Abstract] [Full Text] [Related]
7. Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States.
Hawley JE; Sun T; Chism DD; Duma N; Fu JC; Gatson NTN; Mishra S; Nguyen RH; Reid SA; Serrano OK; Singh SRK; Venepalli NK; Bakouny Z; Bashir B; Bilen MA; Caimi PF; Choueiri TK; Dawsey SJ; Fecher LA; Flora DB; Friese CR; Glover MJ; Gonzalez CJ; Goyal S; Halfdanarson TR; Hershman DL; Khan H; Labaki C; Lewis MA; McKay RR; Messing I; Pennell NA; Puc M; Ravindranathan D; Rhodes TD; Rivera AV; Roller J; Schwartz GK; Shah SA; Shaya JA; Streckfuss M; Thompson MA; Wulff-Burchfield EM; Xie Z; Yu PP; Warner JL; Shah DP; French B; Hwang C;
JAMA Netw Open; 2022 Jan; 5(1):e2142046. PubMed ID: 34982158
[TBL] [Abstract] [Full Text] [Related]
8. Predictive model for recurrence of renal cell carcinoma by comparing pre- and postoperative urinary metabolite concentrations.
Morozumi K; Kawasaki Y; Maekawa M; Takasaki S; Sato T; Shimada S; Kawamorita N; Yamashita S; Mitsuzuka K; Mano N; Ito A
Cancer Sci; 2022 Jan; 113(1):182-194. PubMed ID: 34710258
[TBL] [Abstract] [Full Text] [Related]
9. Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis.
Li X; Zhong X; Wang Y; Zeng X; Luo T; Liu Q
PLoS One; 2021; 16(5):e0250602. PubMed ID: 33939733
[TBL] [Abstract] [Full Text] [Related]
10. Genetic profile and immunohistochemical study of clear cell renal carcinoma: Pathological-anatomical correlation and prognosis.
Diez-Calzadilla NA; Noguera Salvá R; Soriano Sarrió P; Martínez-Jabaloyas JM
Cancer Treat Res Commun; 2021; 27():100374. PubMed ID: 33932757
[TBL] [Abstract] [Full Text] [Related]
11. A population-based study to predict distant metastasis in patients with renal cell carcinoma.
Li Y; Chen P; Chen Z
Ann Palliat Med; 2021 Apr; 10(4):4273-4288. PubMed ID: 33832288
[TBL] [Abstract] [Full Text] [Related]
12. Cyclin Pathway Genomic Alterations Across 190,247 Solid tumors: Leveraging Large-Scale Data to Inform Therapeutic Directions.
Jardim DL; Millis SZ; Ross JS; Woo MS; Ali SM; Kurzrock R
Oncologist; 2021 Jan; 26(1):e78-e89. PubMed ID: 32885893
[TBL] [Abstract] [Full Text] [Related]
13. LncRNA CDKN2B-AS1/miR-141/cyclin D network regulates tumor progression and metastasis of renal cell carcinoma.
Dasgupta P; Kulkarni P; Majid S; Hashimoto Y; Shiina M; Shahryari V; Bhat NS; Tabatabai L; Yamamura S; Saini S; Tanaka Y; Dahiya R
Cell Death Dis; 2020 Aug; 11(8):660. PubMed ID: 32814766
[TBL] [Abstract] [Full Text] [Related]
14. Integrated Analysis of Three Publicly Available Gene Expression Profiles Identified Genes and Pathways Associated with Clear Cell Renal Cell Carcinoma.
Han Y; Wang L; Wang Y
Med Sci Monit; 2020 Jul; 26():e919965. PubMed ID: 32712616
[TBL] [Abstract] [Full Text] [Related]
15. Computational analysis of pathological images enables a better diagnosis of TFE3 Xp11.2 translocation renal cell carcinoma.
Cheng J; Han Z; Mehra R; Shao W; Cheng M; Feng Q; Ni D; Huang K; Cheng L; Zhang J
Nat Commun; 2020 Apr; 11(1):1778. PubMed ID: 32286325
[TBL] [Abstract] [Full Text] [Related]
16. Chromosomal deletion of 9p21 is linked to poor patient prognosis in papillary and clear cell kidney cancer.
Eichenauer T; Simmendinger L; Kluth M; Chirico V; Luebke AM; Höflmayer D; Hinsch A; Jacobsen F; Hube-Magg C; Möller-Koop C; Dahlem R; Fisch M; Rink M; Riechardt S; Tsourlakis MC; Büscheck F; Bernreuther C; Clauditz T; Lebok P; Simon R; Sauter G; Wilczak W; Fraune C
Urol Oncol; 2020 Jun; 38(6):605.e1-605.e8. PubMed ID: 32241691
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic nomograms and Aggtrmmns scoring system for predicting overall survival and cancer-specific survival of patients with kidney cancer.
Zhou Y; Zhang R; Ding Y; Wang Z; Yang C; Tao S; Liang C
Cancer Med; 2020 Apr; 9(8):2710-2722. PubMed ID: 32087609
[TBL] [Abstract] [Full Text] [Related]
18. A pilot investigation of a urinary metabolic biomarker discovery in renal cell carcinoma.
Zhang M; Liu X; Liu X; Li H; Sun W; Zhang Y
Int Urol Nephrol; 2020 Mar; 52(3):437-446. PubMed ID: 31732842
[TBL] [Abstract] [Full Text] [Related]
19. Quantitative enhancement thresholds and machine learning algorithms for the evaluation of renal lesions using single-phase split-filter dual-energy CT.
Obmann MM; Cosentino A; Cyriac J; Hofmann V; Stieltjes B; Boll DT; Yeh BM; Benz MR
Abdom Radiol (NY); 2020 Jun; 45(6):1922-1928. PubMed ID: 31451887
[TBL] [Abstract] [Full Text] [Related]
20. The Alternative 2/1 Schedule of Sunitinib is Superior to the Traditional 4/2 Schedule in Patients With Metastatic Renal Cell Carcinoma: A Meta-analysis.
Sun Y; Li J; Yang X; Zhang G; Fan X
Clin Genitourin Cancer; 2019 Oct; 17(5):e847-e859. PubMed ID: 31279483
[TBL] [Abstract] [Full Text] [Related]
[Next]
